Studies from University of Maryland School of Pharmacy Reveal New Findings on Medicare and Medicaid (Do Restrictions on Antipsychotic Use Differ Between Medicare Part D Stand-Alone Versus Medicare Advantage Plans?)
By a News Reporter-Staff News Editor at Insurance Weekly News Data detailed on Medicare and Medicaid have been presented. According to news reporting out of Baltimore, Maryland, by VerticalNews editors, research stated, "The objective of this study was to describe the type of restrictions and differences among antipsychotic users enrolled in Medicare Part D Stand-Alone (PDPs) and Advantage (MAPDs) prescription drug plans. This retrospective study used data from Chronic Condition Data Warehouse, comprising a random 5% sample of the Medicare population in 2008."
Our news journalists obtained a quote from the research from the University of Maryland School of Pharmacy, "This study used bivariate analyses and multivariate logistical regression models to study differences in formulary restrictions on antipsychotic use between PDP and MAPD enrollees, adjusting for enrollee characteristics. Dependent variables included type of restriction and antipsychotic therapeutic class. The study sample was restricted to continuous Part D enrollees (N=1,346,978) stratified by plan type, MAPDs (N=435,591), and PDPs (N=911,387). According to the bivariate analysis, antipsychotic users enrolled in PDPs were more likely to encounter restrictions (39.8%), compared with those in MAPDs (30.3%). In the multivariate analyses, antipsychotic users in MAPDs were less likely to face any restriction (odds ratio [OR]=0.75, 95% confidence interval [CI] 0.72-0.78). Furthermore, atypical antipsychotic users in MAPDs were less likely to face any restriction (OR=0.76, 95% CI 0.73-0.79), while first-generation antipsychotic users in MAPDs were more likely to face any restriction (OR=1.87, 95% CI 1.32-2.65). Low-income subsidy (LIS) beneficiaries using any antipsychotic were much more likely to face restrictions compared with non-LIS beneficiaries. PDP enrollees prescribed antipsychotics were more likely to face formulary restrictions, as opposed to those in MAPDs."
According to the news editors, the research concluded: "LIS beneficiaries enrolled in PDPs faced much higher risk of restricted access to this 'protected' drug class."
For more information on this research see: Do Restrictions on Antipsychotic Use Differ Between Medicare Part D Stand-Alone Versus Medicare Advantage Plans? The Consultant Pharmacist, 2017;32(2):109-118.
Our news journalists report that additional information may be obtained by contacting J. Chou, Dept. of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, Maryland, United States. Additional authors for this research include N.J. Brandt, F.E. Loh and B. Stuart.
Keywords for this news article include: Antipsychotics, Maryland, Baltimore, United States, Health Policy, Mental Health, Medicare and Medicaid, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC